E-viri
Recenzirano
Odprti dostop
-
Schiaffino, Simone; Pinker, Katja; Cozzi, Andrea; Magni, Veronica; Athanasiou, Alexandra; Baltzer, Pascal A. T.; Camps Herrero, Julia; Clauser, Paola; Fallenberg, Eva M.; Forrai, Gabor; Fuchsjäger, Michael H.; Gilbert, Fiona J.; Helbich, Thomas; Kilburn-Toppin, Fleur; Kuhl, Christiane K.; Lesaru, Mihai; Mann, Ritse M.; Panizza, Pietro; Pediconi, Federica; Sardanelli, Francesco; Sella, Tamar; Thomassin-Naggara, Isabelle; Zackrisson, Sophia; Pijnappel, Ruud M.
Insights into imaging, 07/2023, Letnik: 14, Številka: 1Journal Article
Axillary lymphadenopathy is a common side effect of COVID-19 vaccination, leading to increased imaging-detected asymptomatic and symptomatic unilateral axillary lymphadenopathy. This has threatened to negatively impact the workflow of breast imaging services, leading to the release of ten recommendations by the European Society of Breast Imaging (EUSOBI) in August 2021. Considering the rapidly changing scenario and data scarcity, these initial recommendations kept a highly conservative approach. As of 2023, according to newly acquired evidence, EUSOBI proposes the following updates, in order to reduce unnecessary examinations and avoid delaying necessary examinations. First, recommendation n. 3 has been revised to state that breast examinations should not be delayed or rescheduled because of COVID-19 vaccination, as evidence from the first pandemic waves highlights how delayed or missed screening tests have a negative effect on breast cancer morbidity and mortality, and that there is a near-zero risk of subsequent malignant findings in asymptomatic patients who have unilateral lymphadenopathy and no suspicious breast findings. Second, recommendation n. 7 has been revised to simplify follow-up strategies: in patients without breast cancer history and no imaging findings suspicious for cancer, symptomatic and asymptomatic imaging-detected unilateral lymphadenopathy on the same side of recent COVID-19 vaccination (within 12 weeks) should be classified as a benign finding (BI-RADS 2) and no further work-up should be pursued. All other recommendations issued by EUSOBI in 2021 remain valid. Graphical abstract Key points Worldwide COVID-19 vaccination campaigns have become commonplace. Post-vaccination COVID-19 lymphadenopathy has been reported in up to 44% of cases in at least one follow-up examination. Breast examinations should not be delayed because of COVID-19 vaccination. In average-risk patients without suspicious breast findings, ipsilateral imaging-detected axillary lymphadenopathy within 12 weeks after vaccination should be classified as BI-RADS 2.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.